1 |
郭会芳, 李卓荣. 抗病毒药物的发展和研发策略[J]. 中国医药生物技术, 2017, 12(6): 496-504.
|
2 |
李 耿, 刘晓志, 高 健, 等. 新型抗生素的研发进展[J]. 中国抗生素杂志, 2018, 43(12): 1463-1468.
|
3 |
杨运森, 周健伟, 董志宁, 等. 单纯疱疹病毒IgM抗体 (1+2型) 时间分辨免疫荧光分析法的建立[J]. 热带医学杂志, 2016, 16(12): 1483-1487.
|
4 |
CASTO A M, HUANG M W, XIE H, et al. Herpes simplex virus mistyping due to HSV-1×HSV-2 interspecies recombination in viral gene encoding glycoprotein B[J]. Viruses, 2020, 12(8): 860.
|
5 |
TONG L X, JACKSON J, KERSTETTER J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment[J]. J Am Acad Dermatol, 2014, 70(3): e59-e60.
|
6 |
田文骏, 郑成, 王晓佳. 单纯疱疹病毒 Ⅰ 型最新研究进展——病原学、防控及应用[J]. 生命科学研究,2020, 24(5): 425-430.
|
7 |
HUA L Y, WAKIMOTO H. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application[J]. Expert Opin Biol Ther, 2019, 19(8): 845-854.
|
8 |
SADOWSKI L A, UPADHYAY R, GREELEY Z W, et al. Current drugs to treat infections with herpes simplex viruses-1 and -2[J]. Viruses, 2021, 13(7): 1228.
|
9 |
AWAD S M, ALI S M, MANSOUR Y E, et al. Synthesis and evaluation of some uracil nucleosides as promising anti-herpes simplex virus 1 agents[J]. Molecules, 2021, 26(10): 2988.
|
10 |
ÁLVAREZ D M, CASTILLO E, DUARTE L F, et al. Current antivirals and novel botanical molecules interfering with herpes simplex virus infection[J]. Front Microbiol, 2020, 11: 139.
|
11 |
JAHANGIRI A, OWLIA P, RASOOLI I, et al. Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection[J].Sci Rep,2021,11(1): 1914.
|
12 |
ZHANG L H, XIAO Y R, JI L, et al. Potential therapeutic effects of egg yolk antibody (IgY) in Helicobacter pylori infections─A review[J]. J Agric Food Chem, 2021, 69(46): 13691-13699.
|
13 |
王芳, 张晓晓, 吴兴安. 治疗性抗体在病毒感染性疾病中的应用[J]. 细胞与分子免疫学杂志, 2016, (4): 557-560.
|
14 |
DE MEULENAER B, HUYGHEBAERT A. Isolation and purification of chicken egg yolk immunoglobulins: a review [J]. Food Agric Immunol,2001,13(4): 275-288.
|
15 |
BAO L R, ZHANG C, LYU J L, et al. Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker[J]. J Appl Microbiol, 2022, 132(3): 2421-2430.
|
16 |
KOUJAH L, SURYAWANSHI R K, SHUKLA D. Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea[J]. Cell Mol Life Sci, 2019, 76(3): 405-419.
|
17 |
LUCERO B D, GOMES C R, DE PP FRUGULHETTI I C, et al. Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues[J]. Bioorg Med Chem Lett, 2006, 16(4): 1010-1013.
|
18 |
WANG Y, WANG Q, ZHU Q C, et al. Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children[J]. J Clin Virol, 2011, 52(2): 107-112.
|
19 |
SILVA M T LDA, DEODATO R M, VILLAR L M. Exploring the potential usefulness of IgY for antiviral therapy: a current review[J]. Int J Biol Macromol, 2021, 189: 785-791.
|
20 |
CHEN C J, HUDSON A F, JIA A S, et al. Affordable IgY-based antiviral prophylaxis for resource-limited settings to address epidemic and pandemic risks[J]. J Glob Health, 2022, 12:05009.
|